Tenpoint Therapeutics’ YUVEZZI, projected to launch in the US in Q2 2026, represents the first fixed-dose combination eye drop developed to enhance near vision through pupil modulation with once-daily ...
The deal will see MeiraGTx assume development rights to ZipBio’s experimental therapies targeting the complement pathway in geographic atrophy (GA). Geographic atrophy is characterized by progressive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results